X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (254) 254
Book Chapter (12) 12
Publication (11) 11
Patent (9) 9
Book Review (6) 6
Book / eBook (4) 4
Newspaper Article (3) 3
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (154) 154
oncology (111) 111
index medicus (102) 102
female (72) 72
male (68) 68
middle aged (64) 64
aged (60) 60
cancer (57) 57
adult (56) 56
chemotherapy (51) 51
lung neoplasms - pathology (46) 46
lung neoplasms - drug therapy (38) 38
lung cancer (35) 35
prognosis (35) 35
carcinoma, non-small-cell lung - pathology (33) 33
lung neoplasms - genetics (31) 31
antineoplastic combined chemotherapy protocols - therapeutic use (30) 30
apoptosis (30) 30
carcinoma, non-small-cell lung - drug therapy (30) 30
respiratory system (28) 28
aged, 80 and over (27) 27
treatment outcome (26) 26
neoplasm staging (25) 25
expression (24) 24
lung cancer, non-small cell (24) 24
lung neoplasms - metabolism (24) 24
mutation (23) 23
survival (23) 23
care and treatment (22) 22
hematology, oncology and palliative medicine (22) 22
animals (21) 21
cell line, tumor (21) 21
immunohistochemistry (21) 21
non-small cell lung cancer (21) 21
research (21) 21
angiogenesis (20) 20
antineoplastic agents - therapeutic use (20) 20
carcinoma, non-small-cell lung - genetics (20) 20
analysis (19) 19
cancer therapies (18) 18
carcinoma (18) 18
carcinoma, non-small-cell lung - metabolism (18) 18
cisplatin (18) 18
disease progression (18) 18
metastasis (18) 18
epigenetics (17) 17
cell lung-cancer (16) 16
growth-factor receptor (16) 16
lung neoplasms - mortality (16) 16
mesothelioma (16) 16
nsclc (16) 16
breast-cancer (15) 15
cisplatin - administration & dosage (15) 15
endothelial growth-factor (15) 15
patients (15) 15
biochemistry & molecular biology (14) 14
cell biology (14) 14
gene expression (14) 14
resistance (14) 14
survival rate (14) 14
tumors (14) 14
dna damage (13) 13
mesothelioma - pathology (13) 13
open-label (13) 13
pleural neoplasms - pathology (13) 13
proteins (13) 13
signal transduction (13) 13
biomarkers (12) 12
cell proliferation - drug effects (12) 12
disease-free survival (12) 12
proportional hazards models (12) 12
retrospective studies (12) 12
survival analysis (12) 12
apoptosis - drug effects (11) 11
carcinoma, non-small-cell lung - mortality (11) 11
deoxyribonucleic acid--dna (11) 11
dna methylation (11) 11
gene expression regulation, neoplastic (11) 11
identification (11) 11
lung neoplasms - enzymology (11) 11
physiological aspects (11) 11
1st-line treatment (10) 10
adenocarcinoma - pathology (10) 10
antineoplastic agents (10) 10
antineoplastic agents - pharmacology (10) 10
biomarkers, tumor - metabolism (10) 10
clinical trials (10) 10
deoxycytidine - analogs & derivatives (10) 10
development and progression (10) 10
gefitinib (10) 10
growth (10) 10
health aspects (10) 10
therapy (10) 10
adenocarcinoma (9) 9
antimitotic agents (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
breast cancer (9) 9
cell cycle (9) 9
colorectal-cancer (9) 9
deoxycytidine - administration & dosage (9) 9
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The Journal of Cell Biology, ISSN 0021-9525, 06/2017, Volume 216, Issue 6, p. 1521
Caspase-2 triggers apoptosis, but how it is activated by different stimuli is unclear. In this issue, Ando et al. (2017. J. Cell Biol.... 
Nucleoli | Cellular biology | DNA damage | Caspase | Damage prevention | Cells | Caspase-2 | Deoxyribonucleic acid--DNA | Apoptosis
Journal Article
FUTURE ONCOLOGY, ISSN 1479-6694, 07/2019, Volume 15, Issue 19, pp. 2287 - 2302
Nivolumab and ipilimumab, two therapeutic immune checkpoint inhibitor antibodies that block PD-1 and CTLA-4, respectively, have indications in cancer as single... 
1ST-LINE TREATMENT | CTLA-4 BLOCKADE | nivolumab | SOLID TUMORS | MAINTENANCE BEVACIZUMAB | PHASE-III | atezolizumab | OPEN-LABEL | DOCETAXEL | STAGE IV | pembrolizumab | ANTI-PD-1 ANTIBODY | ONCOLOGY | tumor mutational burden | immunotherapy | ipilimumab | PD-L1 | CTLA-4 | PD-1 | non-small-cell lung cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 22, pp. 2093 - 2104
Journal Article
PLoS ONE, ISSN 1932-6203, 01/2013, Volume 8, Issue 1, p. e54193
Introduction: Inherent and acquired cisplatin resistance reduces the effectiveness of this agent in the management of non-small cell lung cancer (NSCLC).... 
OVEREXPRESSION | ARREST | IN-VITRO | DNA | PHARMACOLOGY | MULTIDISCIPLINARY SCIENCES | SENSITIVITY | AGENTS | COPPER | OVARIAN-CANCER | IDENTIFICATION | Proto-Oncogene Proteins c-met - metabolism | DNA Adducts - drug effects | Homeodomain Proteins - metabolism | Humans | Lung Neoplasms - metabolism | Glycoproteins - metabolism | Lung Neoplasms - pathology | Antigens, CD - metabolism | SOXB1 Transcription Factors - metabolism | Dose-Response Relationship, Drug | Flow Cytometry | Peptides - metabolism | Neoplastic Stem Cells - metabolism | Hyaluronan Receptors - metabolism | Biomarkers, Tumor - metabolism | Antineoplastic Agents - pharmacology | Aldehyde Dehydrogenase - metabolism | Carcinoma, Non-Small-Cell Lung - pathology | Cell Survival - drug effects | Nanog Homeobox Protein | Carcinoma, Non-Small-Cell Lung - metabolism | Cisplatin - pharmacology | AC133 Antigen | beta Catenin - metabolism | Octamer Transcription Factor-3 - metabolism | Cell Line, Tumor | Cell Proliferation - drug effects | Cell Cycle - drug effects | Drug Resistance, Neoplasm - drug effects | Proteins | Cell death | Analysis | Stem cells | Lung cancer, Small cell | Lung cancer, Non-small cell | Cisplatin | Cell proliferation | Health sciences | Biotechnology | Flow cytometry | Dehydrogenases | Oct-4 protein | Lung cancer | DNA damage | Oncology | Cancer therapies | β-catenin | Signal transduction | Platinum | CD44 antigen | Cell cycle | Deoxyribonucleic acid--DNA | G1 phase | Medical research | Subpopulations | Damage assessment | Cell survival | Markers | Non-small cell lung carcinoma | Tumor cell lines | Survival | Medicine | Hospitals | Molecular modelling | Cell lines | Sensitivity enhancement | DNA adducts | Pluripotency | Tumors | Apoptosis | Cancer | Deoxyribonucleic acid
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase
Journal Article
Future oncology (London, England), 05/2019
Nivolumab and ipilimumab, two therapeutic immune checkpoint inhibitor antibodies that block PD-1 and CTLA-4, respectively, have indications in cancer as single... 
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 1, pp. 33 - 42
Summary Background Findings from the phase 3 First-Line ErbituX in lung cancer (FLEX) study showed that the addition of cetuximab to first-line chemotherapy... 
Hematology, Oncology and Palliative Medicine | BREAST-CANCER | BIOMARKERS | GROWTH-FACTOR RECEPTOR | OVEREXPRESSION | ONCOLOGY | PROTEIN EXPRESSION | IN-SITU HYBRIDIZATION | CARCINOMAS | GENE AMPLIFICATION | ESTROGEN-RECEPTOR | III TRIAL | Immunohistochemistry | Lung Neoplasms - drug therapy | Up-Regulation | Prospective Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Patient Selection | Young Adult | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Vinblastine - analogs & derivatives | Aged, 80 and over | Biomarkers, Tumor - metabolism | Brazil | Adult | Female | Biomarkers, Tumor - antagonists & inhibitors | Cetuximab | Odds Ratio | Republic of Korea | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - enzymology | Risk Assessment | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Care and treatment | Patient outcomes | Oncology, Experimental | Research | Lung cancer, Non-small cell | Antineoplastic agents | Antimitotic agents | Cancer patients | Chemotherapy | Product development | Tumors | Cancer
Journal Article
Journal Article
Journal of Cell Biology, ISSN 0021-9525, 06/2017, Volume 216, Issue 6, pp. 1521 - 1523
Caspase-2 triggers apoptosis, but how it is activated by different stimuli is unclear. In this issue, Ando et al. (2017. J. Cell Biol.... 
STRESS | CELL BIOLOGY | Cell Nucleolus | Caspase 2 | DNA Damage | Humans | Apoptosis | Nucleotide sequencing | Observations | DNA damage | Methods | DNA sequencing
Journal Article
Journal Article